Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06518668 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study of NKX019, a CD19 CAR NK Cell Therapy, in Subjects With Systemic Lupus Erythematosus

StatusEnrolling by Invitation
PhasePhase 1
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Lead sponsor: Columbia University to Hospital for Special Surgery, New York
    • Trial status: Suspended to Enrolling by Invitation
    • Study sites: 1 to 2
    • Collaborators expanded, about 2 words
    v4
  2. Trial status: Recruiting to Suspended Sponsor's reason: Study is being transferred to another institution
    • Site details revised
    v3
  3. Site contact updatedv2
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Primary objective: Safety and tolerability of NKX019, administered after lymphodepletion (LD). Secondary objectives: * Assess clinical activity of NKX019 in subjects with systemic lupus erythematosus (SLE) with or without active lupus nephritis (LN) * Characterize pharmacokinetics (PK) of NKX019 * Characterize immunogenicity of NKX019
Trial Details
NCT Number NCT06518668
Lead Sponsor Hospital for Special Surgery, New York
Collaborators: Nkarta, Inc.
Conditions
(from sponsor)		 Systemic Lupus Erythematosus
Related terms Lupus Erythematosus, Systemic, Lupus Nephritis
Enrollment 6 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov